Open Orphan Stock Earnings Reports

hVIVO reported a challenging 2025 financially but significant operational progress and strategic transformation. Revenue for the year was GBP 46.8m, impacted by an unusually high number of study cancellations in mid-2025, but the group still produced a small statutory profit (GBP 1.4m) and ended the year with GBP 14.3m of cash after acquisitions and working capital usage. Management completed two acquisitions (Cryostore and two German clinical research units), rebranded the business under the single hVIVO name and reorganized into four service lines: Consulting (CMC/PK/regulatory), Clinical Trials (Phase I–III and non-challenge trials), Human Challenge Trials (HCTs), and Laboratories (now a stand-alone service). The company has expanded capabilities (new influenza and hMPV challenge models, dPCR and NGS lab equipment) and geographic reach (Germany), and is pursuing a strategy to diversify revenue so HCT no longer dominates income (targeting less than 50% HCT revenue going forward). Post-period highlights include a new influenza prophylactic antiviral HCT (revenues mainly expected in 2026) and an almost-finalized agreement to run the world’s first Phase III human challenge trial in whooping cough with ILiAD (expected to recognize most revenue in 2027). Management expects higher proposal activity (a 50% increase in new proposals in Q1 2026) and guides to high single-digit revenue growth in 2026. The board decided not to pay a 2025 dividend, prioritizing reinvestment and growth.